199 search results for: type 2 inflammation

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization
Type 2 Inflammation
Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim explores the histaminergic and nonhistaminergic mechanisms of itch, highlighting how type 2 cytokines like IL-4 serve as central orchestrators of neuronal sensitization and immune–nervous system cross-talk.

View more
ADVENT at WCI
On Demand
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.

Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
Dermatology
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
expert video

In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation

View more
The Role of IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
.
Congress
1
December
2023
Congress
Global ADVENT FORUM 2023, Dermatology Section | Madrid

New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Pulmonology
Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
Infographic

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

View more
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Dermatology
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
expert video

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

View more
ADVENT On Air | Many Faces of COPD: From Pheno<b>type</b>s to Endo<b>type</b>s
Pulmonology
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes
Podcast

Drs Nicola Hanania and Francesca Polverino explore the Many Faces of COPD: From Phenotypes to Endotypes.

View more
Coverpage
Congress
8
March
2024
Congress
ADVENT at San Diego, 2024

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing <b>Type</b> <b>2</b> Asthma
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more